This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Helicos Announces Nature Publication On First Evidence Of RNA Copying Mechanisms In Human Cells

Helicos BioSciences Corporation (NASDAQ: HLCS) today announced a publication demonstrating the detection and quantification of novel small RNA molecules using Helicos’ single-molecule sequencing technology. These data confirm a long-held, unproven hypothesis that mammalian cells are capable of synthesizing RNA by copying RNA molecules directly. The findings are presented in a paper, entitled “New class of gene-termini-associated human RNAs suggests a novel RNA copying mechanism,” by Kapranov, et al, available today in Nature.

“For the first time, we have evidence to support the hypothesis that human cells have the widespread ability to copy RNA as well as DNA,” said Bino John, Ph.D., assistant professor of computational biology, University of Pittsburgh School of Medicine. “These findings emphasize the complexity of human RNA populations and suggest the important role for single molecule-sequencing for accurate and comprehensive genetic profiling.”

Today’s Nature publication presents joint research findings, utilizing Helicos’ proprietary true Single Molecule Sequencing (tSMS™) technology to profile small RNAs from human cells and tissues. The study uncovered several new classes of RNAs that are produced by uncharacterized RNA copying mechanisms. Such RNA copying mechanisms have been well documented in plants and simple organisms, but this work provides the first supporting evidence for such a mechanism in human cells.

“This class of non-coding RNA molecules has been historically overlooked because available sequencing platforms are often unable to provide accurate detection and quantification,” commented Dr. Patrice Milos, Chief Scientific Officer at Helicos. “This study supports our belief that Helicos’ tSMS technology provides the platform capability to identify and quantitate these RNAs and reinforces the potential clinical advantages of our single molecule-sequencing platform.”

The Nature publication (Vol. 466, No. 7306) was co-authored by Drs. Bino John, A. Paula Monaghan and Sang Woo Kim, of the University of Pittsburgh School of Medicine; Dr. Sylvain Foissac from Integromics, Inc.; Drs. Stylianos Antonarakis and Christelle Borel of the University of Geneva Medical School and Drs. Philipp Kapranov, Doron Lipson, Fatih Ozsolak, Chris Hart, Steve Roels and Patrice Milos of Helicos BioSciences Corporation.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.27 -0.76%
FB $101.00 1.47%
GOOG $684.12 0.89%
TSLA $143.67 -3.09%
YHOO $27.10 1.04%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs